Tissue | Expression Dynamics | Abbreviation |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003461432 | Oral cavity | NEOLP | cellular response to reactive oxygen species | 36/2005 | 155/18723 | 5.51e-06 | 1.13e-04 | 36 |
GO:00603241 | Oral cavity | NEOLP | face development | 16/2005 | 44/18723 | 6.27e-06 | 1.26e-04 | 16 |
GO:004865921 | Oral cavity | NEOLP | smooth muscle cell proliferation | 40/2005 | 184/18723 | 9.53e-06 | 1.82e-04 | 40 |
GO:000749221 | Oral cavity | NEOLP | endoderm development | 22/2005 | 77/18723 | 1.19e-05 | 2.17e-04 | 22 |
GO:004866021 | Oral cavity | NEOLP | regulation of smooth muscle cell proliferation | 39/2005 | 180/18723 | 1.33e-05 | 2.37e-04 | 39 |
GO:000170621 | Oral cavity | NEOLP | endoderm formation | 17/2005 | 54/18723 | 2.91e-05 | 4.46e-04 | 17 |
GO:003598711 | Oral cavity | NEOLP | endodermal cell differentiation | 15/2005 | 45/18723 | 4.02e-05 | 5.71e-04 | 15 |
GO:000736921 | Oral cavity | NEOLP | gastrulation | 38/2005 | 185/18723 | 5.90e-05 | 7.93e-04 | 38 |
GO:000170421 | Oral cavity | NEOLP | formation of primary germ layer | 28/2005 | 121/18723 | 6.25e-05 | 8.31e-04 | 28 |
GO:00603231 | Oral cavity | NEOLP | head morphogenesis | 12/2005 | 32/18723 | 6.38e-05 | 8.40e-04 | 12 |
GO:000110122 | Oral cavity | NEOLP | response to acid chemical | 30/2005 | 135/18723 | 7.75e-05 | 9.93e-04 | 30 |
GO:00603251 | Oral cavity | NEOLP | face morphogenesis | 11/2005 | 28/18723 | 7.84e-05 | 1.00e-03 | 11 |
GO:0010171 | Oral cavity | NEOLP | body morphogenesis | 14/2005 | 43/18723 | 9.66e-05 | 1.18e-03 | 14 |
GO:007122912 | Oral cavity | NEOLP | cellular response to acid chemical | 20/2005 | 80/18723 | 2.25e-04 | 2.37e-03 | 20 |
GO:007123012 | Oral cavity | NEOLP | cellular response to amino acid stimulus | 18/2005 | 71/18723 | 3.79e-04 | 3.57e-03 | 18 |
GO:007121424 | Oral cavity | NEOLP | cellular response to abiotic stimulus | 55/2005 | 331/18723 | 6.38e-04 | 5.43e-03 | 55 |
GO:010400424 | Oral cavity | NEOLP | cellular response to environmental stimulus | 55/2005 | 331/18723 | 6.38e-04 | 5.43e-03 | 55 |
GO:000756531 | Oral cavity | NEOLP | female pregnancy | 36/2005 | 193/18723 | 6.47e-04 | 5.47e-03 | 36 |
GO:007147831 | Oral cavity | NEOLP | cellular response to radiation | 35/2005 | 186/18723 | 6.47e-04 | 5.47e-03 | 35 |
GO:000931432 | Oral cavity | NEOLP | response to radiation | 71/2005 | 456/18723 | 7.84e-04 | 6.25e-03 | 71 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541525 | Endometrium | AEH | Diabetic cardiomyopathy | 86/1197 | 203/8465 | 2.62e-23 | 1.22e-21 | 8.90e-22 | 86 |
hsa0541826 | Endometrium | AEH | Fluid shear stress and atherosclerosis | 43/1197 | 139/8465 | 2.47e-07 | 3.49e-06 | 2.55e-06 | 43 |
hsa0467026 | Endometrium | AEH | Leukocyte transendothelial migration | 37/1197 | 114/8465 | 4.51e-07 | 6.11e-06 | 4.47e-06 | 37 |
hsa0520518 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
hsa049337 | Endometrium | AEH | AGE-RAGE signaling pathway in diabetic complications | 28/1197 | 100/8465 | 2.11e-04 | 1.80e-03 | 1.32e-03 | 28 |
hsa0491525 | Endometrium | AEH | Estrogen signaling pathway | 35/1197 | 138/8465 | 3.10e-04 | 2.40e-03 | 1.75e-03 | 35 |
hsa05415111 | Endometrium | AEH | Diabetic cardiomyopathy | 86/1197 | 203/8465 | 2.62e-23 | 1.22e-21 | 8.90e-22 | 86 |
hsa05418112 | Endometrium | AEH | Fluid shear stress and atherosclerosis | 43/1197 | 139/8465 | 2.47e-07 | 3.49e-06 | 2.55e-06 | 43 |
hsa04670111 | Endometrium | AEH | Leukocyte transendothelial migration | 37/1197 | 114/8465 | 4.51e-07 | 6.11e-06 | 4.47e-06 | 37 |
hsa0520519 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
hsa0493314 | Endometrium | AEH | AGE-RAGE signaling pathway in diabetic complications | 28/1197 | 100/8465 | 2.11e-04 | 1.80e-03 | 1.32e-03 | 28 |
hsa04915111 | Endometrium | AEH | Estrogen signaling pathway | 35/1197 | 138/8465 | 3.10e-04 | 2.40e-03 | 1.75e-03 | 35 |
hsa0541526 | Endometrium | EEC | Diabetic cardiomyopathy | 86/1237 | 203/8465 | 2.59e-22 | 9.46e-21 | 7.05e-21 | 86 |
hsa0541827 | Endometrium | EEC | Fluid shear stress and atherosclerosis | 45/1237 | 139/8465 | 7.76e-08 | 1.22e-06 | 9.07e-07 | 45 |
hsa0467027 | Endometrium | EEC | Leukocyte transendothelial migration | 36/1237 | 114/8465 | 2.97e-06 | 3.91e-05 | 2.91e-05 | 36 |
hsa0520524 | Endometrium | EEC | Proteoglycans in cancer | 52/1237 | 205/8465 | 3.01e-05 | 3.19e-04 | 2.38e-04 | 52 |
hsa0493321 | Endometrium | EEC | AGE-RAGE signaling pathway in diabetic complications | 28/1237 | 100/8465 | 3.68e-04 | 3.03e-03 | 2.26e-03 | 28 |
hsa0491526 | Endometrium | EEC | Estrogen signaling pathway | 34/1237 | 138/8465 | 1.19e-03 | 8.02e-03 | 5.98e-03 | 34 |
hsa0541535 | Endometrium | EEC | Diabetic cardiomyopathy | 86/1237 | 203/8465 | 2.59e-22 | 9.46e-21 | 7.05e-21 | 86 |
hsa0541836 | Endometrium | EEC | Fluid shear stress and atherosclerosis | 45/1237 | 139/8465 | 7.76e-08 | 1.22e-06 | 9.07e-07 | 45 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MMP2 | SNV | Missense_Mutation | | c.1116N>C | p.Lys372Asn | p.K372N | P08253 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MMP2 | SNV | Missense_Mutation | rs759302357 | c.682G>A | p.Ala228Thr | p.A228T | P08253 | protein_coding | deleterious(0) | probably_damaging(0.935) | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD |
MMP2 | SNV | Missense_Mutation | novel | c.1512N>T | p.Met504Ile | p.M504I | P08253 | protein_coding | tolerated(0.2) | benign(0) | TCGA-EW-A6S9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MMP2 | SNV | Missense_Mutation | | c.970G>A | p.Asp324Asn | p.D324N | P08253 | protein_coding | deleterious(0.01) | benign(0.074) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MMP2 | SNV | Missense_Mutation | rs772094112 | c.275N>G | p.Asn92Ser | p.N92S | P08253 | protein_coding | tolerated(0.73) | benign(0) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
MMP2 | SNV | Missense_Mutation | | c.1295G>C | p.Arg432Pro | p.R432P | P08253 | protein_coding | tolerated(0.35) | probably_damaging(0.999) | TCGA-EK-A2PI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
MMP2 | SNV | Missense_Mutation | | c.1116N>C | p.Lys372Asn | p.K372N | P08253 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MMP2 | SNV | Missense_Mutation | | c.1345C>G | p.Pro449Ala | p.P449A | P08253 | protein_coding | deleterious(0.01) | benign(0.001) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MMP2 | SNV | Missense_Mutation | | c.1818C>G | p.Ile606Met | p.I606M | P08253 | protein_coding | tolerated(0.14) | probably_damaging(0.999) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MMP2 | SNV | Missense_Mutation | | c.1896C>G | p.Phe632Leu | p.F632L | P08253 | protein_coding | tolerated(0.24) | probably_damaging(0.966) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | inhibitor | 178101832 | | |
4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | | SERMS | | 15576828 |
4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | | MARIMASTAT | MARIMASTAT | |
4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | | PMID29130358-Compound-SB-3CT | | |
4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | | BMS-275291 | REBIMASTAT | 15041713 |
4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | | SIMVASTATIN | SIMVASTATIN | 16436088 |
4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | | POLYPHENOL | | 15324350 |
4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | | HEPARAN SULFATE | | 12972284 |
4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | | PRAVASTATIN | PRAVASTATIN | 15842807 |
4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | | RO-26-2853 | | |